Skip to Main Content
Phase I

A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

  • Study HIC#:2000028685
  • Last Updated:09/29/2023

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Ingrid Palma

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    Trial Purpose and Description

    Primary Outcome Measures  :

    1. Percentage of Participants With Adverse Events (AEs) [ Time Frame: From baseline up until 28 days after the final dose ]
    2. Percentage of Participants With Dose-Limiting Toxicities (DLTs) [ Time Frame: Days 1-21 of Cycle 1 (a cycle is 21 days) ]
    3. Percentage of Participants With Changes From Baseline in Targeted Vital Signs [ Time Frame: From baseline up until 28 days after the final dose ]
    4. Percentage of Participants With Changes From Baseline in Targeted Clinical Laboratory Test Results [ Time Frame: From baseline up until 28 days after the final dose ]
    5. Percentage of Participants With Changes From Baseline in Targeted ECG Parameters [ Time Frame: From baseline up until 28 days after the final dose ]

    Eligibility Criteria

    Inclusion Criteria:

    • Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.

    Exclusion Criteria:

    • Active brain metastases
    • Malabsorption or other condition that interferes with enteral absorption
    • Clinically significant cardiovascular dysfunction or liver disease

    Sub-Investigators

    For more information about this study, including how to volunteer, contact: